NCT06411821 - Ulixertinib in People With Histiocytic Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Histiocytic Neoplasms

Interventions

DRUG

Ulixertinib

300 mg twice daily, for every 28-day cycle.

Trial Locations (8)

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

RECRUITING

Memorial Sloan Kettering Nassau (Consent Only), Uniondale

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Consent Only), Commack

RECRUITING

Mayo Clinic (Data Collection Only), Rochester

RECRUITING

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only), Montvale